See also this year's filing and all EDGAR filings for this company.
PDF Report 0001070494_2013_Acadia_Pharmaceuticals_INC.pdf
Logs
| warning | No LiabilitiesAndStockholdersEquity node found | input.sec.calculation_linkbase.edgar_model_mapping | {'lase_node': None, 'equity_node': None, 'partners_cap_node': None, 'nodes': "NodeView(('AssetsCurrent', 'Assets', 'PropertyPlantAndEquipmentNet', 'OtherAssetsNoncurrent', 'CashAndCashEquivalentsAtCarryingValue', 'AvailableForSaleSecuritiesCurrent', 'PrepaidExpenseAndOtherAssetsCurrent', 'LiabilitiesCurrent', 'Liabilities', 'DeferredRevenueNoncurrent', 'AccountsPayableCurrent', 'AccruedLiabilitiesCurrent', 'DeferredRevenueCurrent', 'CapitalLeaseObligationsCurrent', 'PreferredStockValue', 'StockholdersEquity', 'CommonStockValue', 'AdditionalPaidInCapital', 'RetainedEarningsAccumulatedDeficit', 'AccumulatedOtherComprehensiveIncomeLossNetOfTax'))"} |
Graph
Absolute values for 0001070494, Acadia Pharmaceuticals INC
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 108,548,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 42,000 |
| 3 | remainder_Assets | 0 |
| 4 | LiabilitiesCurrent | 5,948,000 |
| 5 | LiabilitiesNoncurrent | 0 |
| 6 | remainder_Liabilities | 0 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 6,999,000 |
| 9 | ResearchAndDevelopmentExpense | 18,794,000 |
| 10 | remainder_Expenses | 0 |
| 11 | remainder_Revenues | 4,907,000 |
| 12 | remainder_NetIncome | 37,000 |
| 13 | remainder_ComprehensiveNetIncome | -5,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 108,590,000 |
| 1 | Liabilities | 5,948,000 |
| 2 | Expenses | 25,793,000 |
| 3 | Revenues | 4,907,000 |
| 4 | StockholdersEquity | 102,642,000 |
| 5 | NetIncome | -20,849,000 |
| 6 | ComprehensiveNetIncome | -20,851,500 |
| 7 | BaseVar | 72,640,000 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | 3.54 |
| 9 | EconomicCapitalRatio | 4.06 |
Edgar->Model Mapping
Feature Distribution
Change over Time
